Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

RYTMNYSE / NASDAQHealthcareSmall cap

$112.36-$4.44 (-3.8%)

Last close · Data as of Nov 20, 2026

Market cap
$6.0B
Revenue
$189.8M
Net margin
-106.4%
ROCE
-126.2%

+11.6% over the last year

Rhythm Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+24.6%
3M
+3.2%
6M
+24.0%
1Y
+11.6%
5Y
+990.9%

52-week range

Day change -$4.44 (-3.8%) from $117 to $112 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RYTM, bought on each weekday since 2021.

News & filings

What Rhythm Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 197 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 45.8% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.

Read moreShow less

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
67.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.0B
P/B
22.3x
EV / Sales
29.6x
P/S
31.7x
52-week high
$119.04
52-week low
$75.82

Profitability

Operating margin
-101.2%
Net margin
-106.4%
EBITDA margin
-91.8%
ROE
-74.8%
ROCE
-126.2%
ROIC
-63.1%
ROA
-42.0%
Asset turnover
0.40

Growth

Revenue
$189.8M
Revenue growth, 1Y
45.8%
Revenue CAGR, 3Y
100.2%
Net profit growth, 1Y
-24.6%
Free cash flow
-$116.6M

Solvency

Current ratio
4.41
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.57
Cash / Market cap
6.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$189.8M
Cost of revenue$19.5M
Gross profit$170.3M
Operating expenses$362.3M
Research and development$167.3M
Selling, general and administrative$194.9M
Operating income-$192.0M
Interest and other-$4.0M
Pretax income-$196.0M
Tax and other$500.0k
Net income-$196.5M

Revenue and net profit

Revenue grew 45.8% in FY2025; net profit is the dashed line.

Rhythm Pharmaceuticals, Inc. revenue and net profit by fiscal year
Rhythm Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$23.6M-$181.1M
FY2023$77.4M-$184.7M
FY2024$130.1M-$260.6M
FY2025$189.8M-$196.5M

Cash flows

FY2025: -$115.7M from operations, -$116.6M free after investment (dashed).

Rhythm Pharmaceuticals, Inc. operating and free cash flow by fiscal year
Rhythm Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$173.4M-$177.7M
FY2023-$136.2M-$136.2M
FY2024-$113.9M-$113.9M
FY2025-$115.7M-$116.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$189.8M+45.8%1Y
EBITDA
-$174.1M
Net profit
-$196.5M
Cash from operations
-$115.7M
Free cash flow
-$116.6M
Revenue CAGR, 3Y
100.2%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$189.8M-$174.1M-$196.5M-$116.6M-141.3%+45.8%-24.6%

Monthly returns

Month-by-month returns of RYTM across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$480.2M
Liabilities$210.2M
Equity$270.0M
Paid-in capital$1.5B
Retained earnings-$1.4B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RYTM highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Rhythm Pharmaceuticals, Inc. (this company)29.6x

Not shown (no positive earnings and no EV / Sales): Terns Pharmaceuticals, Inc., Cogent Biosciences, Inc., CRISPR Therapeutics AG.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Rhythm Pharmaceuticals, Inc.RYTMthis company$6.0B—22.3x-74.8%—
Hims & Hers Health, Inc.HIMS$6.5B50.5x12.0x23.7%46.1x
Kymera Therapeutics, Inc.KYMR$6.1B—3.9x-19.7%—
Terns Pharmaceuticals, Inc.TERN$6.1B-63.6x6.1x-9.6%-51.0x
PACS Group, Inc.PACS$5.9B31.0x6.3x20.2%25.0x
Mirum Pharmaceuticals, Inc.MIRM$5.6B-241.4x17.9x-7.4%329.1x
Cogent Biosciences, Inc.COGT$5.6B-17.0x10.2x-60.1%-17.2x
Liquidia CorporationLQDA$5.6B-80.7x124.3x-154.0%-128.8x
CRISPR Therapeutics AGCRSP$5.5B—2.9x-30.3%—
Peer median—-40.3x8.3x-14.6%3.9x

Year-to-date ROI

RYTM since 1 January, against earlier years.

Historical volatility

RYTM's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Rhythm Pharmaceuticals, Inc. operating margin by fiscal year
Rhythm Pharmaceuticals, Inc. operating margin by fiscal year
DateOperating margin
FY2022-757.9%
FY2023-238.1%
FY2024-204.0%
FY2025-101.2%
LineFY2025
Cost of revenueCost Of Revenue$19.5M
Gross profitGross Profit$170.3M
Operating expensesOperating Expense$362.3M
Research and developmentResearch And Development$167.3M
Selling, general and administrativeSelling General And Administration$194.9M
Total expensesTotal Expenses$381.8M
Pretax incomePretax Income-$196.0M

Learn while you research

Academy chapters picked for Rhythm Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing46% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →